Research on the Problems and Countermeasures of the Landing of Negotiated Drugs

Abstract

Objective To provide reference for better landing of the negotiated drugs in the future. Methods Relevant data on the negotiated drugs in designated medical institutions and retail pharmacies from the website of the Medical Security Bureau was obtained, and then the allocation and problems of negotiated drugs were summarized and analyzed. Results and Conclusion The main problem for the landing of negotiated drugs is the difficulty of using them in medical institutions. First, there is a small number of designated medical institutions that can use some negotiated drugs. Second, the negotiated drugs vary greatly in the designated medical institutions. Lastly, some designated retail pharmacies do not supply the negotiated drugs. The difficulties in using the negotiated drugs can include subjective reasons and objective reasons. Retail pharmacies are not the official places where patients can use the negotiated drugs. Besides, if medical institutions do not supply and use negotiated drugs, it will pose a great risk to drug safety. Negotiated drugs should be used in designated medical institutions ultimately, which is conducive to safeguarding the rational drug use for patients.

Keywords

negotiated drug / medical institution / equipment

References

[1] Mao Lining, Wen Xiaotong, Yang ying, et al. Macro analysis and research on the implementation of national drug negotiation - taking Hubei as an example[J]. China Health Insurance, 2021 (11): 76-80.

[2] Chen Lingling, Xu wei, Shang Bobo, et al. Research on the availability of national negotiated drugs - an empirical analysis based on the purchasing data of public hospitals in Suzhou[J]. Health Economics Research, 2020, 37 (12): 17-20.

[3] Chen Jinran, Gou Kaining, Chen chun, et al. Analysis of patients’ accessibility on national negotiation drugs in Fujian Province during 2018-2019[J]. China Health Insurance, 2020 (12): 59-64.

[4] National Healthcare Security Administration, National Health Commission of the People’s Republic of China. Notice on Adapting to the Normalization of National Medical Insurance Negotiation and Continuing the Landing of Negotiated Drugs[EB/OL]. (2021-09-10)[2022-04-02]. http://www.nhsa.gov.cn/art/2021/9/10/art_37_5939.html.

[5] National Healthcare Security Administration. The National Medical Insurance Administration Held a Press Conference on the List of National Medical Insurance Negotiated Drug Allocation Institutions (Second Batch)[EB/OL]. (2021-06-22)[2022-04-02]. http://www.nhsa.gov.cn/art/2021/6/22/art_98_5322.html.

[6] National Healthcare Security Administration, National Health Commission of the People’s Republic of China. Guiding Opinions on Establishing and Improving the “Dual-channel” Management Mechanism for Negotiated Drugs by National Medical Insurance[EB/OL]. (2021-05-10)[2022-04-02]. http://www.nhsa.gov.cn/art/2021/5/10/art_37_5023.html.2021:59-60.

[7] National Healthcare Security Administration. 2021 China Medical Insurance Statistical Yearbook[M]. China Statistics Press, 2021.

[8] National Healthcare Security Administration. Inquiry of the national negotiating drug dispensing agency[EB/OL].(2022-03)[2022-04-02]. http://www.nhsa.gov.cn/.

[9] Lui Wensheng. The difficulty of pharmacy service behind “difficulty in hospitalization of innovative drugs”[J]. China Hospital CEO, 2021, 17 (10): 22-24.

[10] Yao Yao, Xiao Honghao. Analysis on the implementation of drug zero-profit policy[J]. Journal of Jiangxi University of Chinese Medicine, 2012, 24 (3): 77-79.

[11] Office of the State Council. Notice on Printing and Distributing the Main Work Arrangements for Deepening the Reform of the Medical and Health System in 2012[EB/OL]. (2012-04-18)[2022-04-02]. http://www.gov.cn/zwgk/2012-04/18/content_2115928.htm.